Composition for the treatment of fistula

Patent metadata

Field	Value
Publication number	US-10617644-B2
Application number	US-201715691539-A
Country	US
Kind code	B2
Filing date	Aug 30, 2017
Priority date	Oct 3, 2011
Publication date	Apr 14, 2020
Grant date	Apr 14, 2020

Abstract

A composition for use in the treatment of fistula, the composition comprising activated carbon.

First claim

The invention claimed is:

1. A method for the treatment of fistula, the method comprising administering to a subject in need of such treatment a pharmaceutically effective amount of a composition comprising activated carbon of particle size 0.15 mm to 1 mm, wherein the composition is administered rectally as a dry dose, and wherein the activated carbon is driven into the rectum of the subject using a driving fluid, wherein the driving fluid is a gas or a liquid.

2. The method of claim 1 , wherein the activated carbon is of average particle size 0.15 mm to 0.3 mm.

3. The method of claim 1 , wherein 85% or more of the activated carbon particles have diameter in the range from 0.152 mm to 0.297 mm.

4. The method of claim 1 , wherein the fistula is rectal fistula.

5. The method of claim 1 , wherein the amount of activated carbon administered is in the range from 450 μg to 10 g.

6. The method of claim 1 , wherein the activated carbon is granular.

7. The method of claim 1 , wherein the activated carbon is a dry powder of activated carbon which is dust free.

8. The method of claim 1 , wherein the fistula is anal fistula.

9. The method of claim 1 , wherein the activated carbon is ground activated carbon having an irregular particle shape.

10. The method of claim 1 , wherein the composition is administered using a disposable, rectally-insertable, cannula containing the composition.

11. The method of claim 1 , wherein the treatment comprises closing the fistula.

12. The method of claim 1 , wherein the activated carbon is administered twice daily.

13. The method of claim 12 , wherein the treatment comprises closing the fistula within eight weeks of commencing treatment.

14. The method of claim 1 , wherein the treatment is continued for a period of at least 8 weeks.

15. A method for the treatment of fistula, the method comprising administering to a subject in need of such treatment a pharmaceutically effective amount of a composition comprising activated carbon of particle size 0.05 to 0.15 mm, wherein the composition is administered rectally as a dry dose using gas as a driving fluid.

16. The method according to claim 1 , wherein the driving fluid is a gas.

17. The method according to claim 1 , wherein the driving fluid is a liquid.

Assignees

• Ferring Bv

Inventors

• Halskov Soren
• Ekelund Mats

Classifications

• F04C2270/041

  Controlled or regulated · CPC title

• A61K9/14 Primary

  Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} · CPC title

• A61M3/0279

  Cannula; Nozzles; Tips; their connection means · CPC title

• A61M3/022

  Volume; Flow rate · CPC title

• A61K33/44

  Elemental carbon, e.g. charcoal, carbon black · CPC title